Organon & Co. (NYSE:OGN) Reaches New 52-Week High – What’s Next?

Organon & Co. (NYSE:OGN)’s share price hit a new 52-week high during trading on Thursday . The stock traded as high as $13.49 and last traded at $13.4850, with a volume of 68157 shares changing hands. The stock had previously closed at $13.48.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. Zacks Research upgraded Organon & Co. from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 14th. Weiss Ratings upgraded shares of Organon & Co. from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday, May 15th. Piper Sandler raised shares of Organon & Co. from an “underweight” rating to a “neutral” rating and boosted their price objective for the company from $5.00 to $14.00 in a research report on Tuesday, April 28th. Finally, BNP Paribas Exane reissued a “neutral” rating and issued a $14.00 price objective (up from $12.00) on shares of Organon & Co. in a research note on Wednesday, April 29th. Five equities research analysts have rated the stock with a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Reduce” and a consensus price target of $11.40.

Organon & Co. Stock Down 0.0%

The firm has a market cap of $3.54 billion, a P/E ratio of 14.49, a P/E/G ratio of 1.24 and a beta of 1.55. The company has a current ratio of 1.97, a quick ratio of 1.42 and a debt-to-equity ratio of 9.47. The business has a 50-day moving average price of $12.66 and a 200-day moving average price of $9.23.

Organon & Co. (NYSE:OGN) last released its quarterly earnings data on Thursday, April 30th. The company reported $0.71 earnings per share for the quarter, missing the consensus estimate of $0.83 by ($0.12). Organon & Co. had a net margin of 3.99% and a return on equity of 99.95%. The firm had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same quarter in the previous year, the firm earned $1.02 earnings per share. The business’s revenue was down 3.5% compared to the same quarter last year. On average, equities analysts forecast that Organon & Co. will post 3.23 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 11th. Shareholders of record on Monday, May 11th were given a dividend of $0.02 per share. The ex-dividend date of this dividend was Monday, May 11th. This represents a $0.08 dividend on an annualized basis and a yield of 0.6%. Organon & Co.’s dividend payout ratio (DPR) is 8.60%.

Insider Activity at Organon & Co.

In other Organon & Co. news, SVP Lynette Holzbaur purchased 26,448 shares of Organon & Co. stock in a transaction dated Wednesday, May 6th. The stock was acquired at an average price of $13.35 per share, for a total transaction of $353,080.80. Following the acquisition, the senior vice president owned 52,851 shares in the company, valued at $705,560.85. This trade represents a 100.17% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 1.62% of the company’s stock.

Hedge Funds Weigh In On Organon & Co.

Several institutional investors have recently bought and sold shares of OGN. Foster Dykema Cabot & Partners LLC bought a new position in Organon & Co. in the third quarter worth approximately $29,000. Farther Finance Advisors LLC increased its holdings in shares of Organon & Co. by 87.8% in the 4th quarter. Farther Finance Advisors LLC now owns 4,349 shares of the company’s stock valued at $31,000 after acquiring an additional 2,033 shares during the period. Eurizon Capital SGR S.p.A. bought a new position in shares of Organon & Co. in the 4th quarter worth $44,000. Kestra Advisory Services LLC bought a new position in shares of Organon & Co. in the 4th quarter worth $47,000. Finally, WNY Asset Management LLC purchased a new stake in shares of Organon & Co. during the 1st quarter worth $64,000. 77.43% of the stock is owned by hedge funds and other institutional investors.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.